Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950126 | 0.90 | ACACB (0.55) | NAMPTHDAC6HDAC1PRMT5WDR77 | |
| SCHEMBL10120396 | 0.82 | HDAC6 (0.49) | HDAC6HDAC1HDAC8 | |
| SCHEMBL10120395 | 0.82 | HDAC6 (0.51) | HDAC6HDAC1HDAC8KDM1APRMT5 | |
| SCHEMBL12896044 | 0.77 | SMN1; SMN2 (0.62) | HDAC6HDAC1HDAC8ACACBPOLB | |
| SCHEMBL9959114 | 0.77 | ACACB (0.58) | PRMT5WDR77MCHR1ACACBPOLB | |
| SCHEMBL12895811 | 0.76 | HDAC1 (0.76) | HDAC6HDAC1HDAC8PRMT5WDR77 | |
| SCHEMBL1264338 | 0.75 | HDAC6 (0.65) | HDAC6HDAC1HDAC8POLB | |
| SCHEMBL1263457 | 0.74 | HDAC6 (0.62) | HDAC6HDAC1HDAC8KDM1AACACB | |
| SCHEMBL9949404 | 0.74 | HDAC6 (0.58) | HDAC6HDAC1HDAC8ESR2 | |
| SCHEMBL1264249 | 0.74 | TNF (0.66) | HDAC6HDAC1HDAC8KDM1AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | NAMPT 1596/4885HDAC6 1/4885HDAC1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.